Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity and mortality throughout the world.
Diagnosis and Assessment of COPD (Gold 2018)
• COPD should be considered in any patient who has dyspnoea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease.
• Spirometry is required to make the diagnosis; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation.
• Routine reversibility testing is not normally indicated in COPD.
• Formal accreditation of healthcare professionals (HCPs) in COPD and spirometry is advised. HCPs should have access to high quality spirometry and be competent in the interpretation of the results.
• It is advisable that any HCP undertaking spirometry should have a certificate of competence from the Association for Respiratory Technology and Physiology (ARTP) following completion of either the Foundation (level 1) course or the Full Certificate (level 3).
• The goals of COPD assessment are to determine the severity of the disease, including the severity of airflow limitation, the impact of the disease on the patients' health status, and the risk of future events (such as exacerbations, hospital admissions or death), in order to guide therapy.
• Concomitant chronic diseases occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety and lung cancer. These comorbidities should be actively sought and treated appropriately when present as they influence mortality and hospitalisations independently.
• In addition to initial spirometric assessment, patients should have an assessment of symptoms, frequency of exacerbations, Body Mass Index (BMI), exercise tolerance and the Medical Research Council (MRC) dyspnoea score recorded at least annually. The COPD Assessment Tool (CAT) can be used as a validated measure of patients symptoms (www.catestonline.org ).
• Patients with more severe disease should be reviewed at least twice a year, which should include documented pulse oximetry values and weight.
• Chest X-ray: there should be a low threshold for referral for chest X-ray, as patients with COPD are at high risk of lung cancer.
Smoking and smoking cessation
• 20% of all smokers will develop COPD whilst 50% of smokers will die of a smoking related illness.
• 30% of patients continue to smoke after a diagnosis of COPD because smoking is a nicotine addiction.
• Within a few months of starting to smoke there is a 300% increase in nicotine receptors in the brain that release dopamine. They never ever disappear.
• It takes 2-3 months for the receptors to 'go to sleep' and they can be reactivated with one cigarette.
• 70% of smokers want to stop, 30% try each year and only 2-3% succeed without support.
• Motivation to stop alone is not a predictor of success. Evidence suggests successful quits are achieved by a combination of patient motivation and good quality behavioural support, with pharmacotherapy/NRT (see table) .
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No pharmacotherapy Pharmacotherapy/NRT
Will power alone 2-3% success 4-6% success Support from trained advisor 10-15% success 20-30% success
• It is important to see smoking cessation as a therapeutic treatment not just lifestyle advice. Stopping smoking is the single most evidence-based change a patient with COPD can make. Take every opportunity to encourage supported smoking cessation, however severe the COPD and regardless of age.
• For patients who wish to discuss and seek further advice regarding the use of E-cigarettes/Vaporisers as an aid to smoking cessation refer to the Stop Smoking Services for the correct advice and support.
Pulmonary rehabilitation
People with COPD and self-reported exercise limitation (mMRC 2-4) should be offered pulmonary rehabilitation. Referrals are also accepted for patients with functional limitation due to other chronic respiratory diseases. Patients who have been hospitalised with an acute exacerbation of COPD should be offered referral for pulmonary rehabilitation to reduce the risk of subsequent readmissions. All patients are encouraged to continue exercising after pulmonary rehabilitation and are offered the option of referral to community COPD classes which are held at local leisure centres. The community classes are held at Macclesfield, Wilmslow, Congleton, Crewe, Nantwich and Sandbach leisure centres. Brio Leisure hold classes in Winsford and Northwich.
Palliative care A variety of criteria may be used to guide appropriateness for the palliative care (Gold Standards Framework) register, including the level of their symptoms, carer support needs, level of lung function or the response to the question 'would you be surprised if they died in the next twelve months?'. Patients should have access to appropriate therapies and services offered by multidisciplinary teams. Further guidance is available on www.cheshire-epaige.nhs.uk and later in these guidelines.
Vaccinations Ensure annual Influenza vaccination and check Pneumococcal immunisation status.
Ensure multidisciplinary working COPD care should be delivered by a multidisciplinary team pertinent to the severity of the patient's condition (NICE 2010).
Clinical research:
Offer patients the opportunity to participate in clinical research.
Making a diagnosis (NICE 2010)
Reassess diagnosis in view of response to treatment:
• Clinically significant COPD is not present if FEV1 and FEV1/FVC ratio return to normal with drug therapy • Asthma may be present if: -FEV1 response of 12% or increase of 200mls in volume post short acting beta-2 agonist. This is considered a positive response. ->400ml response to bronchodilators. This response strongly suggests Asthma.
-serial peak flow measurements show significant (≥ 20%) diurnal or day to day variability • Specialist referral is recommended for patients with a restrictive pattern on spirometry and for all patients in whom alpha-1 antitrypsin deficiency is suspected.
• Specialist referral for further investigation may also be appropriate at all stages of the disease and not solely in the most severely disabled patients.
For all people with diagnosed COPD:
• Highlight the diagnosis of COPD in notes and clinical system using Read codes (or Snomed)
• Record the results of spirometric tests at diagnosis -both absolute and percentage of predicted values Consider a diagnosis of COPD for people who are over 35 and smokers or ex-smokers with any of the following:
• exertional breathlessness, chronic cough, regular sputum production, frequent winter 'bronchitis' and wheeze • and who do not have the clinical features of Asthma (chronic unproductive cough, significantly variable breathlessness and/or wheeze and significant diurnal or day to day variability of symptoms).
Perform initial diagnostic evaluation if COPD seems likely:
• Post-bronchodilator spirometry (record absolute and percentage of predicted values). Assess severity of airflow obstruction according to the tables on the following page.
• Chest X-ray to exclude other diagnoses (investigate abnormalities using a CT scan).
• Consider alternative diagnoses in older people without typical symptoms of COPD and FEV1/FVC ratio < 0.7, and younger people with symptoms of COPD and FEV1/FVC ratio > 0. 
Persistent breathlessness
Key; SABA short acting beta agonist;
LAMA long acting muscarinic antagonist; LABA long acting beta agonist; ICS inhaled corticosteroid.
Preferred treatment indicated by Specialist initiation
In patients with a major discrepancy between the perceived level of symptoms and severity of airflow limitation, further evaluation is warranted. 
Inhaled therapy in COPD
Concordance
• Check concordance with prescribed medicines if there is poor control, and address issues such as poor inhaler technique, lack of understanding of the purpose of each device, exacerbation plans and understanding of the repeat prescribing process.
• Review all changes in therapy after 4 weeks to assess benefit of change and any adverse effects.
• Community pharmacists can support patients with inhaler technique during Medicines Use Reviews (MURs) or the New Medicines Service (NMS) consultations, and patients may find it helpful to watch videos of correct inhaler technique (via NHS choices, British Lung Foundation, YouTube etc).
• If patients need a spacer, they should be advised to inhale one actuation at a time and to clean the device monthly with water and washing up liquid and air dry. Patients can be provided with a new spacer annually, at their review appointment.
Bronchodilators
• All patients should have access to a short acting bronchodilator. SABA as salbutamol MDI is the preferred choice for the majority of patients. Patients using SABA regularly and asking for 2 each month should be reviewed and treatment optimised according to local guidelines.
• LAMAs are the preferred first-line long acting bronchodilators, with the choice of agent being determined by cost and patient preference for the device. As tiotropium and glycopyrronium levels are increased with reduced renal function the benefit v risk of continuing in moderate to severe impairment must be considered. No dosage adjustment is required for aclidinium or umeclidinium in renal impairment. LABAs may be trialled if LAMAs are not tolerated / contraindicated. • The LAMA + LABA combination inhalers are more cost effective for patients with persistent breathlessness, compared with the separate component devices. If patients who have had LAMA + LABA device for increasing symptoms develop exacerbations, consider a change to a triple therapy device.
• The only short-acting antimuscarinic (SAMA) available is ipratropium, which may be an alternative or addition to a SABA in some patients. Ipratropium should be stopped before starting any LAMA. Patients are no longer recommended to commence a SAMA, as there is a range of LAMAs to choose from, which frequently makes a SAMA obsolete. Legacy patients on a SAMA may be considered for a change to a LAMA, particularly if the patient is breathless during the night.
Inhaled Corticosteroids
• The main role of ICS in COPD is to reduce the risk of exacerbations. However, patients with asthma /COPD overlap syndrome should be treated primarily according to asthma guidelines where the ICS devices have a more prominent role. ICS monotherapy is not licensed or recommended in COPD.
• ICS treatment is associated with increased risk of non-fatal pneumonia. Risks may outweigh benefits in mild to moderate COPD. Follow GOLD guidelines and only use ICS in patients who are exacerbating two or more times per year or with one severe exacerbation leading to hospitalisation.
• Patients who have previously used a combination LAMA + LABA device for breathlessness may need to be changed to a triple therapy device if they develop exacerbations.
Central and Eastern Cheshire Local Health Economy Formulary Choices for Inhaled Therapy in COPD Exacerbation management
Community and self-management of exacerbations Patients with moderate or severe COPD should develop a written plan for self-management of exacerbations in conjunction with a named Primary Care contact (usually a practice nurse).
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How to minimise • Be aware of local weather forecasts and conditions. Advise patients to avoid the risks of an going out in adverse weather conditions and if this cannot be avoided advise to exacerbation wrap up warmly and wear a hat in cold spells.
• Advise patients to use alcohol hand gels to reduce infection risk.
• Encourage smoking cessation and advise patients to avoid passive smoking as well.
How to recognise
A sustained worsening of symptoms from the usual stable state that is worse an exacerbation than usual day to day variability and comes on suddenly. Symptoms of an exacerbation may include:
• 
Post-exacerbation
All patients should be reviewed after each exacerbation, ideally within 1-2 weeks review of resolution of symptoms. This review should include:
• Review of self-management plans, inhaler technique, understanding of how/when to use the medication, and ability to cope in usual environment • Record FEV1 (once stable) using COPD6 or equivalent and consider need for chest X-ray • Review of treatment regimen according to local Guidelines • Smoking cessation advice and immunisations (if necessary).
Monitoring in primary care
The degree of airflow obstruction, as measured by FEV1, doesn't always correlate with patient symptoms but can guide therapy. Airway obstruction should be monitored annually, but following a good initial diagnostic spirometry test Micro spirometry is recommended for monitoring purposes (e.g. the COPD6). The use of the COPD6 or equivalent will save 20-30 minutes of spirometry time per patient thus freeing up valuable time for patient assessment, support and education.
Annual assessment should include:
• An assessment of change in symptoms since last review More severely affected patients should be assessed at least twice a year.
Pulse oximetry should be conducted in addition to the assessments listed above in patients with FEV1<30% predicted.
Hospital management of exacerbations
Many exacerbations can be managed successfully in the community, and the decision to admit to hospital should be taken on clinical grounds. Patients who may struggle to cope at home for social reasons (e.g. lives alone, isolated) may be suitable for community care / additional social support services. Patients with any of the following should be considered for admission to hospital: The risk of death from an exacerbation is closely related to the development of respiratory acidosis, presence of significant comorbidities and the need for ventilatory support.
Supported early discharge (SED) can reduce the duration of hospitalisation for patients with resolving exacerbations. SED is co-ordinated by the IRT.
All patients who develop hypoxaemia (low arterial blood oxygen concentration) during an exacerbation should be reviewed and assessed by the IRT as an inpatient. This will include an assessment for home oxygen therapy, based on national guidelines. This group of patients should be followed up at 4-6 weeks postdischarge by Secondary Care or the IRT. This should be clearly documented on their discharge information.
If home oxygen is appropriate on discharge, blood gases should be taken both on discharge and at 8 weeks post discharge. If the patient remains hypoxaemic they should be assessed for long term oxygen therapy (LTOT) by IRT in accordance with British Thoracic Guidelines (BTS) Home Oxygen Assessment Guidelines (2015). For those patients newly prescribed oxygen it is especially important that there is good communication between the practice team and the IRT or secondary care.
The risk of readmission after hospital discharge is 9% at one week and 18% at one month. The 90-day mortality for this group of patients is around 15%.
It remains best practice for all patients to be reviewed in primary care, ideally within 1-2 weeks of discharge.
The IRT will review identified housebound patients, and other patients who may require more intensive supervision by the IRT. The IRT will communicate fully with the practice.
A risk assessment approach should be adopted for assessing safety of all forms of home oxygen, especially in smokers in line with BTS recommendations, local home oxygen team and oxygen provider.
E-cigarettes may represent a fire hazard and are considered to pose the same risk as cigarettes when assessing for oxygen use.
Oxygen does not treat breathlessness in the absence of hypoxaemia. Treatment with palliative oxygen therapy does not have a role in patients with cancer or end-stage cardiorespiratory disease with intractable breathlessness if their resting saturations are normal or only mildly hypoxaemic.
Pulmonary Rehabilitation
Pulmonary rehabilitation (PR) is an evidence-based intervention that both increases a patient's wellbeing and ability to manage their condition and also reduces symptom levels and admission to hospital. It is an important intervention in the management of patients with long term chronic respiratory disease. If patients have any conditions that may affect their ability to participate in an exercise session please inform PR. The patients must be motivated and committed to complete the course and be able to provide their own transport.
There are services available that may help with non-emergency transport including the Red Cross. For East Cheshire patients referrals can be made directly to the pulmonary rehabilitation service via referral form, clinic letter or IRT referral proforma. The referral form must be completed fully. Central Cheshire referrals can be made directly to the PR team via referral form or clinic letter or by emailing tmc-tr.communityrehabteam@nhs.net
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Additional considerations
Nebulised Therapy
When it is clinically necessary, patients should be supplied with an NHS nebuliser. This should be supplied by the Acute Trust when necessary on discharge or supplied by the IRT when the patient is managed in the community. Generally, GPs should only prescribe nebulised therapy on the recommendation of the IRT.
• Nebulised therapy can be used short-term as part of managing exacerbations at home, but ideally only after appropriate assessment by the IRT.
• Nebulised therapy may be used as a component of supported early discharge following an exacerbation and will be reviewed by the IRT once the acute exacerbation has settled.
• Longer term nebuliser treatment may be necessary (rarely) when breathlessness is not adequately controlled with usual inhaled therapy or if specialised nebulised medication such as antibiotics or hypertonic saline is required.
Mucolytics (Carbocisteine, Acetylcysteine)
Do not routinely use mucolytic drugs to prevent exacerbations in people with stable COPD (NICE CG101). Do not initiate mucolytic therapy during an exacerbation. Before prescribing mucolytics, ensure that the patient has had education on chest clearance techniques, posture and exercise. It is important that there is a formal review following a trial of mucolytic therapy as side effects are common and effectiveness varies. Only continue beyond 4 weeks if there is symptomatic improvement (for example, reduction in frequency of cough and improved sputum production).
Mucolytics should be used with caution in the elderly, in patients with a history of gastrointestinal ulcers or with medications known to cause gastric bleeding. Carbocisteine and acetylcysteine are included in the local formulary -please check for cost effective options. Carbocisteine may be initiated as a trial dose of 750mg three times daily for 4 weeks and reduced to a maintenance dose of 750mg twice a day or 375mg four times daily if a satisfactory response is obtained. Acetylcysteine may cause bronchospasm and should not be prescribed to patients with asthma. Discontinue acetylcysteine immediately if bronchospasm occurs. Erdosteine is not included in the local formulary.
Oral Theophylline -specialist initiation only
Theophylline may have a role in patients with persistent symptoms despite other treatments; any patient being considered for oral theophylline should be referred to specialist services who will initiate treatment if appropriate. Plasma levels need to be monitored and any potential drug interactions considered, particularly in smokers. Levels should be checked in patients who stop smoking or reduce their cigarette / nicotine use.
Particular caution needs to be taken with the use of theophylline in older people because of the differences in pharmacokinetics, the increased likelihood of comorbidities and the use of other medications.
The effectiveness of theophylline treatment should be assessed by improvements in symptoms, activities of daily living, exercise capacity and lung function.
The dose of theophylline prescribed should be reduced at the time of an exacerbation if a macrolide or quinolone antibiotic (or other drug known to interact) is prescribed.
Oral Corticosteroid therapy
Maintenance use of oral corticosteroid therapy in COPD is not recommended. In exceptional circumstances, some patients with advanced COPD may receive maintenance oral corticosteroids when these cannot be withdrawn following an exacerbation. In these cases, the dose of oral corticosteroids should be kept as low as possible and the prescriber should ensure that the patient has a Steroid card (obtained from Primary Care Services England [PCSE] ).
Patients treated with both frequent courses (>3 courses in 12 months) or long-term oral corticosteroid therapy should be monitored for the development of osteoporosis and given appropriate prophylaxis -see NICE CG146.
Leukotriene Receptor Antagononist (LTRA)
LTRA (montelukast) are not licensed in COPD. However some patients may also have a co-existing history of atopy/Allergic Rhinitis where a LTRA may be of benefit.
Phosphodiesterase-4-enzyme inhibitor (PDE4) -specialist initiation only
Roflumilast (Daxas) is an orally administered long-acting selective PDE4. It is recommended as a treatment option for treating severe chronic obstructive disease in adults with chronic bronchitis. It is only recommended when:
• The disease is severe, defined as a post-bronchodilator FEV1 of less than 50% of predicted normal • The person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid.
Guidance for use
